Featured Articles

1. From LNP Delivery To Functional CAR-T: Rethinking Targeting 10/16/2026

   Optimizing LNPs for in vivo CAR-T requires aligning target selection, formulation design, and delivery performance to achieve functional CAR expression in desired T-cell populations while balancing specificity, safety, dosing flexibility, and manufacturability.

2. The Checklist For Evaluating In-Vivo CAR-T Manufacturing Partners 10/16/2026

   Choosing the right in vivo CAR-T manufacturing partner requires looking beyond cost to the capabilities that protect scalability, compliance, safety, and development timelines.

3. All You Need To Know About GMP Manufacturing Of mRNA-LNP Drug Products 10/13/2026

   Moving mRNA-LNP production from lab to GMP scale exposes tensions among formulation consistency, regulatory expectations, and facility safety, while automation offers ways to resolve them.

4. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

   Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

5. Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids 10/13/2026

   Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.

6. Can Targeted LNP Delivery Take In-Vivo CAR-T Therapy Beyond The Liver? 9/17/2026

   Achieving successful extrahepatic CAR T delivery with LNPs requires addressing the unique biological and technological barriers and designing targeting approaches that leverage innovative LNP design.

7. Transforming Gene Therapy With A Scalable Platform Solution 9/15/2026

   Discover how a platform approach to AAV manufacturing can reduce development time and cost, as well as how optimized processes enable reliable production and scalable implementation in bioreactors.

8. Enabling Effective Passive And Active Immune Cell Targeting Strategies 8/10/2026

   Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.

9. Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles 7/1/2026

   Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.

10. Neoantigen-Based Personalized Cancer Vaccine 7/1/2026

    Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.